StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a report released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reduced their price target on Trevena from $225.00 to $125.00 and set a buy rating on the stock in a research report on Thursday, May 16th.
View Our Latest Stock Report on TRVN
Trevena Stock Down 15.4 %
Trevena (NASDAQ:TRVN – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($9.25) by $9.02. The firm had revenue of $0.33 million for the quarter. As a group, equities research analysts expect that Trevena will post -1.29 EPS for the current fiscal year.
Institutional Investors Weigh In On Trevena
A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVN – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena at the end of the most recent quarter. 13.56% of the stock is currently owned by hedge funds and other institutional investors.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Stories
- Five stocks we like better than Trevena
- The 3 Best Retail Stocks to Shop for in August
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks That Could Beat the September Blues
- How Can Investors Benefit From After-Hours Trading
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.